UH
MYGN icon

Unigestion Holding’s Myriad Genetics MYGN Stock Holding History

Unigestion Holding’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-60,735
Closed -$2.02M – 257
2019
Q1 		$2.02M Hold
60,735
– – 0.05% 153
2018
Q4 		$1.77M Buy
+60,735
New +$2.18M 0.04% 193

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Unigestion Holding's MYGN Position: Q2 2019 in Review

Unigestion Holding sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 60,735 shares — an estimated $2.02M sold.

Unigestion Holding first reported a position in MYGN in Q4 2018 and held it in 2 quarters. The position peaked at $2.02M in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Unigestion Holding reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Unigestion Holding sold 60,735 Myriad Genetics shares in Q2 2019, an estimated $2.02M.
  • Unigestion Holding first reported a position in Myriad Genetics in Q4 2018 and held it in 2 quarters.
  • Unigestion Holding's Myriad Genetics position peaked at $2.02M in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Unigestion Holding's 13F filing for Q2 2019, filed 15 Jul 2019.